What is the ROCE (Return on Capital Employed) of Imugene this year?
The ROCE of Imugene is -1.72 undefined this year.
Imugene ROCE 2025
Imugene ROCE
-1.72
Ticker
IMU.AX
ISIN
AU000000IMU9
WKN
891460
In 2025, Imugene's return on capital employed (ROCE) was -1.72, a 726.81% increase from the -0.21 ROCE in the previous year.
Imugene Aktienanalyse
What does Imugene do?
Imugene Ltd is an Australian biotechnology company focused on the development of immunotherapies for various diseases, including cancer and infectious diseases. The company was founded in 2014 and is headquartered in Sydney. Imugene's business model is based on collaboration with academic institutions and other biotechnology companies to identify and develop promising drug candidates. The company also works closely with clinical researchers and physicians to accelerate drug development and ensure they meet patient needs. Imugene specializes in four different areas: oncology, immunology, infectious diseases, and neuroscience. Each area focuses on the development of drugs for specific diseases and medical needs. In the field of oncology, Imugene is focused on developing immunotherapy products for the treatment of breast cancer, colon cancer, lung cancer, and other types of cancer. Immunotherapy aims to strengthen the body's immune system to better destroy cancer cells. In the field of immunology, Imugene is focused on developing immunotherapy products for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Immunotherapy aims to modulate the immune system to eliminate disease-causing cells. In the field of infectious diseases, Imugene is focused on developing vaccines and products for the treatment of diseases such as COVID-19, influenza, hepatitis B, and HPV. Vaccines aim to activate the immune system to recognize and destroy pathogens before they can cause harm in the body. In the field of neuroscience, Imugene is focused on developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. These drugs aim to stimulate the brain's neuroprotective mechanisms to reduce nerve damage. Imugene has several promising products in the pipeline that aim to demonstrate the efficacy and safety of immunotherapy and other therapies. The company has already conducted clinical trials for some of these products, while others are still in preclinical development. One of Imugene's key products is HER-Vaxx, a vaccine for the treatment of breast cancer that activates the body's immune system against the HER2 protein, which promotes cancer growth in some individuals. The vaccine has been tested in clinical trials and has shown promising results. Another promising product from Imugene is PD1-Vaxx, a vaccine for the treatment of lung cancer that targets the activation of an important immune cell sensor. Preliminary study results suggest that treatment with PD1-Vaxx is synergistic with checkpoint inhibitors, another type of cancer treatment medication. Imugene is also working on a range of products for the treatment of COVID-19, including IMM-013, a vaccine against SARS-CoV-2, and IMM-036, an antibody against the virus. These products are being tested in preclinical development and are aimed at helping to contain the spread of the pandemic. Overall, Imugene aims to develop innovative drugs for the treatment of various medical needs. The company relies on close collaboration with academic and clinical partners to accelerate drug development and ensure its products meet the highest standards of efficacy and safety. Imugene ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Imugene's Return on Capital Employed (ROCE)
Imugene's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Imugene's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Imugene's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Imugene’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Imugene stock
How has the ROCE (Return on Capital Employed) of Imugene developed compared to the previous year?
The ROCE of Imugene has increased by 726.81% increased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Imugene?
A high Return on Capital Employed (ROCE) indicates that Imugene has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Imugene?
A low ROCE (Return on Capital Employed) can indicate that Imugene has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Imugene impact the company?
An increase in the ROCE of Imugene can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Imugene affect the company?
A decrease in ROCE of Imugene can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Imugene?
Some factors that can affect Imugene's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Imugene so important for investors?
The ROCE of Imugene is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Imugene take to improve the ROCE?
To improve the ROCE, Imugene can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Imugene pay?
Over the past 12 months, Imugene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Imugene is expected to pay a dividend of 0 AUD.
What is the dividend yield of Imugene?
The current dividend yield of Imugene is .
When does Imugene pay dividends?
Imugene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Imugene?
Imugene paid dividends every year for the past 0 years.
What is the dividend of Imugene?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Imugene located?
Imugene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Imugene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Imugene from 9/26/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.
When did Imugene pay the last dividend?
The last dividend was paid out on 9/26/2025.
What was the dividend of Imugene in the year 2024?
In the year 2024, Imugene distributed 0 AUD as dividends.
In which currency does Imugene pay out the dividend?
The dividends of Imugene are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Imugene
Our stock analysis for Imugene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imugene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
